Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with companies executive. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Recently Added News
Belkin’s Automated, Contactless Laser for Glaucoma Gains CE Marking
Israel’s Belkin Vision announced May 16 that its Eagle automated laser treatment for glaucoma received CE marking. The Eagle is the first contactless laser for glaucoma. Controlled rollout of the s...
UK is First in Europe to Approve Teva’s Lucentis Biosimilar Ongavia
Israel’s Teva Pharmaceutical Industries announced May 17 that the UK’s Medicines & Healthcare Regulatory Agency (MHRA) had granted marketing approval to Ongavia, a Lucentis (ranibizumab) biosimilar...
Visionix to Distribute Righton Products in Europe, the Americas, and Select Asia Pacific Countries
Visionix, formerly Luneau Technology, and Japan’s Right MFG announced May 16 that they had entered a long-term strategic partnership agreement. Financial terms of the deal were not disclosed. Visio...
Skye to Acquire Emerald in Stock Deal, List on Canadian Securities Exchange
Cannabis companies Skye Bioscience and Emerald Health Therapeutics announced May 12 that they had signed a deal for Skye to acquire all shares of Emerald in a share-for-share transaction that inclu...
Brim Partners with Ora for Phase III Trial of Dry Eye Candidate
Brim Biotechnology, of Taiwan, announced May 17 that it had partnered with ophthalmic research company Ora on a Phase III clinical trial, set to begin in Q4-2022, for Brim’s lead drug candidate, BR...
Formosa, AimMax See Positive Results in Phase III Trial of Post-cataract Inflammation, Pain Candidate
Formosa Pharmaceuticals and AimMax Therapeutics reported positive results May 12 from the first of two pivotal Phase III studies of APP13007, a novel ophthalmic nanosuspension of the corticosteroid...
Visiox Pharma Appoints Ryan S. Bleeks as Chief Executive Officer
Visiox Pharma, which is advancing new formulations of well-known ophthalmic compounds, announced May 17 that it had appointed Ryan S. Bleeks as chief executive officer. Previously, Bleeks was vice ...
Zhaoke Licenses Visus’ Presbyopia Drop Candidates for Greater China, South Korea, Select Southeast Asian Markets
Visus Therapeutics announced May 11 that Hong Kong’s Zhaoke Ophthalmology had signed an exclusive licensing agreement for the development and commercialization of presbyopia drop candidates Brimoch...
Q1-2022 Ophthalmic Revenue Roundup for Alcon, Glaukos, Aerie, Harrow, and Eight Others
Alcon reported May 10 that its Q1-2022 sales were $2.2 billion, an increase of 14 percent over $1.9 billion in Q1-2021. Surgical net sales increased 17 percent and totaled $1.3 billion, consisting ...
Orbis Opens 18 Solar-Powered ‘Green Vision Centers’ in India
The non-profit group Orbis International announced April 22 the recent opening of 18 so-called Green Vision Centers, aiming to bring quality eye care to children in rural communities in India’s Ker...
Oxurion Drops DME Candidate After Disappointing Phase II Results
Belgium’s Oxurion reported May 9 that it would not advance THR-687, a pan-RGD integrin inhibitor, into the second part of its Phase II trial in diabetic macular edema (DME), after disappointing top...
EyePoint Expands Licensing Deal with Betta for Wet AMD Candidate in Greater China
EyePoint Pharmaceuticals, maker of Yutiq and Dexycu, announced May 4 that it had expanded its licensing agreement with China’s Betta Pharmaceuticals to develop and commercialize EYP-1901 for wet ag...
Past News Stories
Switzerland’s SAV-IOL Unveils its Instant Focus EDOF IOL Technology
Swiss company SAV-IOL unveiled on May 5 its Instant Focus EDOF (extended depth of focus) optical technology for its intraocular lenses (IOLs). The company says that, unlike other EDOF technologies,...
Zeiss Offers New SLT Add-On for Visulas Green Laser
Carl Zeiss Meditec announced May 4 that it now offers a selective laser trabeculoplasty (SLT) add-on to its Visulas green laser, part of its integrated Glaucoma Workflow. SLT is based on the photot...
Catalyst Regains Rights to C3 Inhibitor for Dry AMD
Catalyst Biosciences reported May 9 in its Q1-2022 earnings summary that it had regained the rights to CB 2782-PEG, a complement C3 inhibitor, from Biogen for the potential treatment of dry age-rel...
ABVC BioPharma Revamps Manufacturing of Vitargus Ahead of Clinical Trials
ABVC BioPharma, formerly known as American BriVision, announced May 5 a new manufacturing process for its vitreous substitute candidate Vitargus, in preparation for upcoming clinical studies. ABVC ...
Belite Bio Earns FDA Fast Track Nod for Oral Stargardt Candidate
Belite Bio announced May 3 that LBS-008 (tinlarebant), its oral treatment candidate for Stargardt, had been granted fast track designation by the US FDA. LBS-008 has already been granted rare pedia...
Vedere Bio II Appoints Anna-Maria Demetriades, MD, PhD, as Chief Medical Officer
Vedere Bio II announced April 26 that it had appointed Anna-Maria Demetriades, MD, PhD, as chief medical officer. The Cambridge, Massachusetts, company was founded by the leadership and research te...
Glaucoma Pharma Market Sees Growing Tug-of-War Between Rising Treatment, Lower Prices
Generic competitors to previously unchallenged brand name products in the US are keeping the lid on revenue from glaucoma pharmaceuticals. Teva Pharmaceutical Industries launched the first US FDA-a...
Bausch + Lomb Sets IPO Share Price at $18, Begins Trading on NYSE
Bausch + Lomb announced May 5 that it had priced its initial public offering at $18 per share, below its targeted $21 to $24 range reported in an SEC filing on April 28. The stock began trading May...
Q1-2022 Ophthalmic Revenue Roundup for Regeneron, Horizon, Allergan, STAAR, Lumibird
Regeneron, of Tarrytown, New York, reported May 4 that its Q1-2022 US revenue for Eylea was $1.52 billion, a 13 percent increase over $1.35 billion in Q1-2021. Regeneron’s collaboration revenue rel...
CorneaGen Introduces Preloaded Graft Insertion Device for DSEK
CorneaGen announced April 28 the release of its EndoSerter-PL, a new US FDA approved, single-use graft insertion device preloaded with processed tissue to help streamline Descemet’s stripping endot...
J&J Vision Appoints Peter Menziuso as Company Group Chairman Over Surgical, Vision Care Units
Johnson & Johnson Vision announced May 3 that it had appointed Peter Menziuso as company group chairman. Menziuso will oversee the two units that make up J&J Vision—Johnson & Johnson Surgical Visio...
Ocuphire Concludes Pediatric Safety Trial for Nyxol, Plans NDA Filing for Reversal of Mydriasis in Late 2022
Ocuphire Pharma announced April 28 that it saw positive results in the MIRA-4 pediatric safety trial of Nyxol for the reversal of pharmacologically induced mydriasis (dilation of pupil). Nyxol’s ef...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.